Clinical Trial Update: DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) [Phase 3]

View source ↗

Summary

Phase 3 ASCENT-2 trial evaluating DN-101 in combination with docetaxel for androgen-independent prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DN-101
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Novacea | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED